[go: up one dir, main page]

RU2006116252A - Водные композиции, содержащие метронидазол - Google Patents

Водные композиции, содержащие метронидазол Download PDF

Info

Publication number
RU2006116252A
RU2006116252A RU2006116252/15A RU2006116252A RU2006116252A RU 2006116252 A RU2006116252 A RU 2006116252A RU 2006116252/15 A RU2006116252/15 A RU 2006116252/15A RU 2006116252 A RU2006116252 A RU 2006116252A RU 2006116252 A RU2006116252 A RU 2006116252A
Authority
RU
Russia
Prior art keywords
compositions containing
water compositions
containing metronidazole
cyclodextrin
beta
Prior art date
Application number
RU2006116252/15A
Other languages
English (en)
Other versions
RU2413501C2 (ru
Inventor
Юник ЧАНГ (US)
Юник ЧАНГ
Гордон Дж. ДАУ (US)
Гордон Дж. ДАУ
Original Assignee
Дау Фармасьютикал Сайенсиз (Us)
Дау Фармасьютикал Сайенсиз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21872727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2006116252(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дау Фармасьютикал Сайенсиз (Us), Дау Фармасьютикал Сайенсиз filed Critical Дау Фармасьютикал Сайенсиз (Us)
Priority to RU2006116252/15A priority Critical patent/RU2413501C2/ru
Publication of RU2006116252A publication Critical patent/RU2006116252A/ru
Application granted granted Critical
Publication of RU2413501C2 publication Critical patent/RU2413501C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075—Macromolecular gels
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2301/00—Characterised by the use of cellulose, modified cellulose or cellulose derivatives
    • C08J2301/02—Cellulose; Modified cellulose
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
    • C08J2305/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Materials Engineering (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (1)

  1. Способ получения водного раствора, содержащего бета-циклодекстрин в концентрации более 0,5% мас./мас., включающий комбинирование в водной жидкости бета-циклодекстрина и ниацинамида или ниацина, где количество ниацинамида или ниацина, которое комбинируют в водной жидкости, достаточно для того, чтобы обеспечить концентрацию растворенного бета-циклодекстрина более 0,5% мас./мас. при температуре 5°С.
RU2006116252/15A 2001-12-24 2006-05-11 Способ получения водного раствора, содержащего бета-циклодекстрин RU2413501C2 (ru)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2006116252/15A RU2413501C2 (ru) 2001-12-24 2006-05-11 Способ получения водного раствора, содержащего бета-циклодекстрин

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/033,835 US6881726B2 (en) 2001-12-24 2001-12-24 Aqueous compositions containing metronidazole
US10/033,835 2001-12-24
RU2006116252/15A RU2413501C2 (ru) 2001-12-24 2006-05-11 Способ получения водного раствора, содержащего бета-циклодекстрин

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2004122696/15A Division RU2284810C2 (ru) 2001-12-24 2002-11-07 Водные композиции, содержащие метронидазол

Publications (2)

Publication Number Publication Date
RU2006116252A true RU2006116252A (ru) 2007-12-10
RU2413501C2 RU2413501C2 (ru) 2011-03-10

Family

ID=21872727

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2004122696/15A RU2284810C2 (ru) 2001-12-24 2002-11-07 Водные композиции, содержащие метронидазол
RU2006116252/15A RU2413501C2 (ru) 2001-12-24 2006-05-11 Способ получения водного раствора, содержащего бета-циклодекстрин

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2004122696/15A RU2284810C2 (ru) 2001-12-24 2002-11-07 Водные композиции, содержащие метронидазол

Country Status (19)

Country Link
US (4) US6881726B2 (ru)
EP (3) EP2241320A1 (ru)
JP (1) JP4611632B2 (ru)
KR (1) KR100718858B1 (ru)
CN (1) CN100411624C (ru)
AR (1) AR037755A1 (ru)
AT (1) ATE481105T1 (ru)
AU (1) AU2002340458B2 (ru)
BR (1) BRPI0215331B8 (ru)
CA (1) CA2470492C (ru)
CY (1) CY1111095T1 (ru)
DE (1) DE60237710D1 (ru)
DK (1) DK1467744T3 (ru)
ES (1) ES2352656T3 (ru)
MX (1) MXPA04006210A (ru)
PT (1) PT1467744E (ru)
RU (2) RU2284810C2 (ru)
WO (1) WO2003057135A2 (ru)
ZA (1) ZA200405059B (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468989B1 (en) * 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
DE10306453A1 (de) * 2003-02-17 2004-08-26 Deutsche Telekom Ag Administrator
US7456207B2 (en) * 2003-09-25 2008-11-25 Teva Pharmaceuticals Usa, Inc. Vaginal pharmaceutical compositions and methods for preparing them
FR2866566A1 (fr) * 2004-02-20 2005-08-26 Galderma Res & Dev Utilisation d'un inhibiteur de la secretion d'il-5,il-6 et/ou il-10 pour le traitement de la rosacee
FR2887149B1 (fr) * 2005-06-17 2007-08-03 Galderma Sa Procede de solubilisation du metronidazole
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
ATE498027T1 (de) * 2005-12-07 2011-02-15 Univ Ramot Wirkstoffabgebende verbundkörper
ES2439582T3 (es) * 2007-03-12 2014-01-23 Dsm Ip Assets B.V. Composiciones cosméticas
US20080287513A1 (en) * 2007-05-14 2008-11-20 Jerry Zhang Topical compositions containing metronidazole
US20080287514A1 (en) * 2007-05-14 2008-11-20 Jerry Zhang Topical compositions containing metronidazole
US20080312304A1 (en) * 2007-06-13 2008-12-18 Jerry Zhang Topical compositions containing metronidazole
CN101795694B (zh) * 2007-09-04 2012-10-10 明治制果药业株式会社 注射剂、注射液和注射用试剂盒制剂
AR061947A1 (es) * 2008-01-08 2008-08-10 Oscar Belluscio Daniel Metodo para la obtencion del complejo gonadotrofina corionica humana (gch) / ciclodextrina administrable por via oral, producto obtenido con dicho metodo y uso clinico-terapeutico del complejo gonadotrofina corionica humana (gch) / ciclodextrina
US7893097B2 (en) 2008-02-02 2011-02-22 Dow Pharmaceutical Sciences, Inc. Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
US20110091515A1 (en) * 2008-06-12 2011-04-21 Ramot At Tel-Aviv University Ltd. Drug-eluting medical devices
US8729108B2 (en) * 2008-06-17 2014-05-20 Christopher J Dannaker Waterborne topical compositions for the delivery of active ingredients such as azelaic acid
WO2010047831A1 (en) * 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
EP2201930A1 (en) 2008-12-23 2010-06-30 Intendis GmbH Hydrogel composition for the treatment of dermatological disorders
US20120129819A1 (en) * 2009-04-14 2012-05-24 Medortus (Uk) Ltd Gel compositions for administration of pharmaceutically active compounds
CN105903028B (zh) * 2010-12-31 2020-10-16 东塘实验室有限公司 含有环糊精的细胞水合组合物
JP2014502612A (ja) * 2010-12-31 2014-02-03 イーストポンド・ラボラトリーズ・リミテッド シクロデキストリンを含有する細胞水和組成物
US20120171184A1 (en) 2010-12-31 2012-07-05 Lajos Szente Cellular hydration compositions
CN103327965B (zh) 2011-01-25 2017-07-18 宝洁公司 脂质体和包含脂质体的个人护理组合物
EP2725904B1 (en) 2011-06-28 2024-12-11 Chemo Research SL High dosage mucoadhesive metronidazole aqueous-based gel formulations their use to treat bacterial vaginosis
US9511144B2 (en) 2013-03-14 2016-12-06 The Proctor & Gamble Company Cosmetic compositions and methods providing enhanced penetration of skin care actives
EP2952208A1 (en) * 2014-06-04 2015-12-09 Universidade de Santiago de Compostela Hydroalcoholic system for nail treatment
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
JP2015044850A (ja) * 2014-11-07 2015-03-12 イーストポンド・ラボラトリーズ・リミテッド シクロデキストリンを含有する細胞水和組成物
US9492374B2 (en) * 2015-03-25 2016-11-15 Jose Rafael Salinas Andrade Composition and method for treatment of ulcers
US10835517B2 (en) 2017-12-15 2020-11-17 Tarsus Pharmaceuticals, Inc. Methods for treating ocular demodex using isoxazoline parasiticide formulations
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device
CN111840632A (zh) * 2019-04-25 2020-10-30 广东泰宝医疗科技股份有限公司 一种含止血微囊的液体敷料及其制备方法
AU2021284155A1 (en) * 2020-06-02 2023-01-05 National University Of Singapore Compositions, their uses in therapy and methods thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032645A (en) * 1975-06-19 1977-06-28 G. D. Searle & Co. Injectable metronidazole composition
US4267169A (en) * 1978-07-22 1981-05-12 Toko Yakuhin Kogyo Kabushiki Kaisha Novel preparation of clotrimazole
GB8330969D0 (en) * 1983-11-21 1983-12-29 Wellcome Found Promoting healing
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4837378A (en) * 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5536743A (en) 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
ES2058503T5 (es) 1988-03-29 1999-04-16 Univ Florida Formulaciones farmaceuticas para uso parenteral.
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
RU2029548C1 (ru) * 1989-07-07 1995-02-27 Центр по химии лекарственных средств Антимикробное или радиосенсибилизирующее средство
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
TW200402B (ru) 1990-08-13 1993-02-21 Senju Pharma Co
US5747341A (en) * 1991-06-24 1998-05-05 Pacific Biomedical Research, Inc. Culture media having low osmolarity for establishing and maintaining hormone-secreting cells in long-term culture
AU2228592A (en) * 1991-06-24 1993-01-25 Pacific Biomedical Research, Inc. Hormone-secreting cells maintained in long-term culture
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
MX9604411A (es) * 1994-03-28 1997-12-31 Univ Columbia Composicion para inactivar irritantes en fluidos.
FR2722098B1 (fr) * 1994-07-06 1996-08-23 Cird Galderma Nouveaux medicaments a base de metro-nidazole ou d'un melange synergetique de metronidazole et de clindamycine
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
CA2301304A1 (en) * 1997-08-27 1999-03-04 Hexal Ag New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
US6017516A (en) * 1997-10-31 2000-01-25 Lekar Pharma Limited Pharmaceutical dental formulation for topical application of metronidazole benzoate and chlorhexidine gluconate
US6183766B1 (en) * 1999-02-12 2001-02-06 The Procter & Gamble Company Skin sanitizing compositions
US6468989B1 (en) * 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
CN1116038C (zh) * 2000-11-18 2003-07-30 雷文彬 一种治疗痤疮的外用药液

Also Published As

Publication number Publication date
US20080154030A1 (en) 2008-06-26
CN100411624C (zh) 2008-08-20
JP4611632B2 (ja) 2011-01-12
EP1467744A4 (en) 2006-07-05
EP1467744B1 (en) 2010-09-15
US20100048659A1 (en) 2010-02-25
CA2470492A1 (en) 2003-07-17
WO2003057135A3 (en) 2003-12-18
PT1467744E (pt) 2010-11-30
RU2284810C2 (ru) 2006-10-10
RU2004122696A (ru) 2005-03-20
EP2241320A1 (en) 2010-10-20
DE60237710D1 (de) 2010-10-28
AR037755A1 (es) 2004-12-01
EP2238980A1 (en) 2010-10-13
WO2003057135A2 (en) 2003-07-17
RU2413501C2 (ru) 2011-03-10
US7348317B2 (en) 2008-03-25
ATE481105T1 (de) 2010-10-15
US20050124578A1 (en) 2005-06-09
KR100718858B1 (ko) 2007-05-16
AU2002340458A1 (en) 2003-07-24
AU2002340458B2 (en) 2007-01-04
CN1649603A (zh) 2005-08-03
ES2352656T3 (es) 2011-02-22
CY1111095T1 (el) 2015-06-11
CA2470492C (en) 2010-02-23
MXPA04006210A (es) 2005-05-17
KR20040075911A (ko) 2004-08-30
BRPI0215331B8 (pt) 2021-05-25
DK1467744T3 (da) 2010-12-20
US20030119783A1 (en) 2003-06-26
BRPI0215331B1 (pt) 2015-07-28
BR0215331A (pt) 2005-05-10
HK1071514A1 (en) 2005-07-22
EP1467744A2 (en) 2004-10-20
US6881726B2 (en) 2005-04-19
ZA200405059B (en) 2005-09-28
JP2005532990A (ja) 2005-11-04

Similar Documents

Publication Publication Date Title
RU2006116252A (ru) Водные композиции, содержащие метронидазол
EP1236398A4 (en) MICROBICIDAL COMPOSITIONS
WO2005046360A3 (en) Carbohydate and electrolyte replacement composition
BR0206619A (pt) Aperfeiçoamentos em ou relativos a composições detergentes lìquidas
WO2004039159A8 (en) Active bromine containing biocidal compositions and their preparation
DK1100344T3 (da) Chitosanholdige flydende præparater og fremgangsmåder til deres fremstilling og anvendelse
FR2826270B1 (fr) Lingette et ses utilisations dans le domaine cosmetique
DK1273756T3 (da) Overfladeaktive sammensætninger til bröndrensning
NO20040329L (no) Termisk stabile bronnkompletteringsfluider med hoy densitet
DE60026722D1 (de) Biozide anwendungen von konzentrierten wässrigen bromchlorid-lösungen
WO2002070404A3 (en) Stabilised hypobromous acid solutions
DE50210284D1 (de) Bioregulatorische wirkstoffkombination
DE60232018D1 (de) 3-phenyl-2-arylalkylthiopropionsäure-derivate als selektive agonisten von ppar-alpha
RU97107034A (ru) Способ лечения синдрома сухого глаза
RU2001126413A (ru) Жидкая среда для низкотемпературной консервации биологических трансплантатов
ITRM20030087A1 (it) Metodo, impianto e composizione chimica del fluido
RU2002112409A (ru) Способ подготовки призабойной зоны скважины перед кислотной обработкой
RU2002117929A (ru) Антиоксидантное средство
RU2002135879A (ru) Состав для водоизоляции низкотемпературных пластов
RU2002101633A (ru) Жидкость для глушения скважин
RU2002103574A (ru) Способ обработки бурового раствора на водной основе
RU2001113592A (ru) Буровой раствор
RU96106807A (ru) Буровой раствор
RU2000123952A (ru) Промывочная жидкость для бурения вечномерзлых пород
ES2179763A1 (es) Nueva formulacion desinfectante y conservante, procedimiento para su preparacion y sus aplicaciones.